PACIRA BIOSCIENCES, INC. Goodwill, Foreign Currency Translation Gain (Loss)
PACIRA BIOSCIENCES, INC. (PCRX) reported Goodwill, Foreign Currency Translation Gain (Loss) of $400.00 thousand for the 12-month period ending 2025-12-31, per its 10-Q filed 2026-04-30.
Financial Statements › Income Statement › Other Income
us-gaap:GoodwillForeignCurrencyTranslationGainLoss · last filed 2026-08-04
- PACIRA BIOSCIENCES, INC. goodwill, foreign currency translation gain (loss) for the quarter ending 2025-12-31 was -$1.82M.
- PACIRA BIOSCIENCES, INC. goodwill, foreign currency translation gain (loss) for the quarter ending 2025-09-30 was $1.62M.
- PACIRA BIOSCIENCES, INC. goodwill, foreign currency translation gain (loss) for the quarter ending 2025-06-30 was -$157.00K.
- PACIRA BIOSCIENCES, INC. goodwill, foreign currency translation gain (loss) for the quarter ending 2025-03-31 was $757.00K.
| Period end | Goodwill, Foreign Currency Translation Gain (Loss) 3 month | Goodwill, Foreign Currency Translation Gain (Loss) 6 month | Goodwill, Foreign Currency Translation Gain (Loss) 6 month as first filed | Goodwill, Foreign Currency Translation Gain (Loss) 9 month | Goodwill, Foreign Currency Translation Gain (Loss) 12 month | Goodwill, Foreign Currency Translation Gain (Loss) 12 month as first filed |
|---|---|---|---|---|---|---|
| 2025-12-31 | -$1.82M derived: 10-Q 12 month − 10-Q 9 month · filed 2026-04-30 | -$200.00K derived: sum of 2 quarters · filed 2026-04-30 | -$357.00K derived: sum of 3 quarters · filed 2026-08-04 | $400.00K 10-Q · filed 2026-04-30 | $2.23M 10-K · filed 2026-02-26 | |
| 2025-09-30 | $1.62M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $1.46M derived: sum of 2 quarters · filed 2026-08-04 | $2.22M 10-Q · filed 2025-11-06 | |||
| 2025-06-30 | -$157.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04 | $600.00K 10-Q · filed 2026-08-04 | $2.20M 10-Q · filed 2025-08-05 | |||
| 2025-03-31 | $757.00K 10-Q · filed 2025-05-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |